Public – private partnership: Telix Pharmaceuticals – nuclear oncology, 15 April 2018

The SIRIC is proud to announce the partnership of the Nantes nuclear medicine oncology network with the Australian company Telix Pharmaceuticals:

We are pleased to be working with Telix to progress the use of astatine in a clinical setting. This partnership is a great example of translational research aiming at truly personalized medicine in France and beyond. The clinical translation of astatine therapy will be performed in the nuclear medicine department of Nantes Centre Hospitalier Universitaire (CHU) and l’Institut de Cancérologie de l’Ouest  (ICO) chaired by Professor Françoise Kraeber-Bodéré, in collaboration with the Labex IRON network (Innovative Radiopharmaceuticals in Oncology and Neurology) and “Le SIRIC ILIAD” (Imaging and Longitudinal Investigations to Ameliorate Decision-making in Multiple Myeloma and Breast Cancer).

Professor Michel Chérel (team leader, INSERM University of Nantes) and Dr Jean-Francois Gestin (radiochemistry development).

Read the full press release of the Telix – nuclear oncology partnership